Ocugen's Bahamas Approval Meets a Shareholder Reckoning: Inside the 250 Million Share Question

Ocugen won Bahamas provisional approval for OCU400, but a deferred October 5 shareholder vote on 250 million new shares keeps dilution risk in focus.

Ocugen has spent October walking a tightrope that will feel familiar to anyone who has tracked a clinical-stage gene therapy company. On one side sits a genuine regulatory milestone in the Bahamas and a crowded slate of scientific presentations. On the other, a deferred shareholder vote on a massive expansion of authorized shares hangs over the stock like a storm cloud that refuses to move.

The company's shares closed Friday at EUR 0.9110, a level that captures the tension neatly. That price sits 29% below the 200-day moving average of EUR 1.29 and miles away from the 52-week high of EUR 2.35. The market, in other words, is not handing out credit for promises.

A Caribbean Green Light With a Long Runway

The clearest win came on September 25, when the Longevity and Regenerative Therapies Board of the Bahamas granted OCU400 a provisional approval along with priority review status. Ocugen intends to make the candidate available through an expanded access program, with the first retinitis pigmentosa patient targeted for treatment within 90 days of a full approval.

It is an encouraging step, but investors should keep the commercial scale in perspective. A Bahamian approval opens early treatment options; it does not substitute for US market access, where the timelines stretch considerably further. Phase 3 topline data for OCU400 are not expected until the first quarter of 2027, and the BLA submission is penciled in for the second quarter of that same year.

The pipeline does not stand still in the meantime. Twelve-month results from the Phase 2 ArMaDa study of OCU410 are slated for presentation on October 9 and 11 at the American Academy of Ophthalmology meeting. Ocugen is also showcasing its modifier gene therapy platform at international gatherings, including Euretina events in Vienna and a GARDian1 study poster running October 1 through 4.

The Capital Question That Won't Go Away

However promising the science looks, the financial scaffolding casts a long shadow. Roughly two weeks ago, shareholders postponed a vote on a proposal to increase authorized common stock by 250,000,000 shares, pushing the decision to October 5 at 8:00 a.m. ET. SEC filings indicate the delay was meant to give investors more time to review and cast their ballots.

A capital increase of that magnitude sends an unmistakable signal: fresh money will be needed. For existing holders, that translates directly into dilution risk. When a resolution has to be deferred, it rarely points to unanimous support at the base — and the market's skepticism is easy to understand.

Adding to the caution was management's own behavior. About a month ago, CEO Shankar Musunuri sold 468,727 directly held shares and 57,264 indirectly held shares at weighted average prices of USD 1.12. The transactions followed a Rule 10b5-1 trading plan adopted on June 5, 2026. Such sales are formally pre-arranged, yet they still weigh on sentiment during a period of open financing questions. Since that disclosure, the stock has shed 20.9%.

Taking the Message to the Industry Stage

To shore up investor confidence, the leadership team is stepping up its public presence. Musunuri is participating in several industry panels during October, including the Cell & Gene Meeting on the Mesa on October 6. That platform offers management a chance to refocus the conversation on the therapeutic potential of its product candidates rather than the balance sheet.

Whether the scientific narrative can outrun the financing overhang is the central question. The modifier gene therapy platform may rest on sound science, but in the late stage of a development cycle, the market cares most about financial runway. Until the outcome of the postponed October 5 vote is known, sustained recoveries will have a hard time gaining traction. Anyone holding the stock should be watching that ballot closely — it is the pivot on which the coming months turn.